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Abstract
Background: Histiocytic sarcoma (HS) is a rare malignant tumor. Underlying or associated disorders have been
reported in some patients with HS. We herein report a very rare case of HS combined with acute monocytic
leukemia (AMoL).
Case presentation: A 62-year-old man presented with systemic lymph node enlargement and pancytopenia in
August 2012. Bone marrow (BM) aspirate showed abnormal hematopoiesis with 3 % blast, but no obvious
abnormalities on flow cytometric immunophenotyping. A BM cytogenetic study and fluorescence in situ
hybridization revealed a 46, XY karyotype and no myelodysplastic syndrome-associated features, respectively. A
right cervical node biopsy showed disrupted node structure with diffuse pleomorphic neoplastic cells that were
positive for cluster of differentiation (CD) 68, MAC387 and lysozyme, but negative for CD1a, CD21, CD30, S100, and
T-cell, B-cell, and myeloid lineage markers. The patient was diagnosed with HS and treated with 8 courses of CHOP
chemotherapy. After 4 courses, total-body FDG-PET imaging showed partial remission and disappearance of
abnormal hematopoiesis in the BM, but 2 % blasts remained. Lymphadenopathy and pancytopenia recurred
1 month after the his last chemotherapy dose. He became resistant to second-line chemotherapy, with gradually
increasing leukocytes, up to 50 % blasts in BM in December 2013, and abnormal cells positive for CD117, CD13,
CD33, HLA-DR, CD34, CD11c, CD38, and myeloperoxidase. He was diagnosed with acute monocytic leukemia
(AMoL-M5), and treated by CAG regimen + decitabine, but died of severe pneumonia and hepatic failure.
Conclusion: To our knowledge, this is the first case of HS combined with AMoL. The coexistence of these two
neoplasms was shown by the lymph node biopsy findings and BM myeloid markers. The patient had a transient
response to chemotherapy and a poor prognosis. Whether these two neoplasms were related is unclear; however,
if so, we suspect the combination might be caused by a malignant transformation of a promonocyte or stem cell,
upstream of histiocytes and monocytes.
Keywords: Histiocytic sarcoma, Acute monocytic leukemia, Relationship
Background
Histiocytic sarcoma (HS) is an extremely rare malignant
neoplasm, accounting for less than 1 % of all hemato-
lymphoid neoplasms [1]. It is believed to be derived
from monocyte/macrophage lineage and shows morpho-
logic and immunophenotypic features of mature tissue
histiocytes. According to the 2001 and 2008 World
Health Organization (WHO) classifications [1, 2], HS
cells are immunohistochemically positive for one or more
histiocytic markers such as cluster of differentiation (CD)
68 (KP1, PGM1), CD163, and lysozyme, but negative for
CD1a, CD21, CD35, CD30, and T-cell, B-cell, and mye-
loid lineage markers. S100 can be positive but usually
weak or focal. Ki67 is variable. With the development of
immunohistochemical (IHC) techniques, most previous
reported cases of HS are now generally recognized to be
misdiagnosed examples of non-Hodgkin lymphomas, pre-
dominantly diffuse large B-cell lymphoma, or anaplastic
cell lymphoma.
Interestingly, many reports have described the associ-
ation of HS with other neoplasms, especially hematologic
malignancies, the most common of which are lympho-
cytic leukemia/lymphomas, such as follicular lymphoma
[3, 4], mantle cell lymphoma [5], mucosa-associated
* Correspondence: nxq_0988@163.com
1Department of Hematology, Zhongshan Hospital of Xiamen University,
Xiamen 361004, Fujian, China
Full list of author information is available at the end of the article
© 2015 Zhao et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhao et al. Diagnostic Pathology  (2015) 10:110 
DOI 10.1186/s13000-015-0350-9
lymphoid tissue lymphoma [6], diffuse large B-cell lymph-
oma [7], acute lymphoblastic leukemia [8–11] and
chronic lymphocytic leukemia [12], chronic myelomono-
cytic leukemia (CMML) [13], mediastinal germ cell
tumors [14, 15], and idiopathic myelofibrosis [16]. More-
over, HS has been shown to share molecular or cytogen-
etic features with the associated neoplasms in most of
these cases.
We herein report a case involving a 62-year-old man
who was initially diagnosed with HS and later found to
have acute monocytic leukemia (AMoL). To our know-
ledge, this is the first reported case of HS combined with
AMoL.
Case presentation
A 62-year-old Chinese man presented with gingival
bleeding in August 2012. Physical examination revealed
skin ecchymosis and enlarged lymph nodes in his cer-
vical, axillary, and inguinal areas, the largest of which
was 3 × 2 cm. Neither hepatosplenomegaly nor spleno-
megaly was noted. A complete blood count showed pan-
cytopenia with a hemoglobin level of 11.1 g/dL, white
blood cell (WBC) count of 2.92 × 109/L (47.9 % neutro-
phils, 1.7 % monocytes, and 47.2 % lymphocytes), and
platelet count of 21 × 109/L. A bone marrow (BM) aspir-
ate was hypercellular with 75.5 % myeloid cells, 19.5 %
erythroid cells, and 4.5 % lymphocytes. Abnormal
hematopoiesis was present in the granulocyte, erythroid,
and megakaryocytic series to different extents, with 3 %
blasts (Fig. 1a). However, flow cytometry (FCM) immu-
nophenotyping of the BM showed no obvious abnormal-
ities. A BM cytogenetic study revealed a 46, XY
karyotype. Fluorescence in situ hybridization of the BM
showed no myelodysplastic syndrome-associated karyo-
type [i.e., del (5q), del (20q), or +8 or del (7q)]. Total-
body FDG-PET imaging revealed systemic lymphaden-
opathy (maximum standardized uptake value of 6.4). A
right cervical lymph node biopsy showed disrupted node
structure with effacement by diffuse distribution of
pleomorphic neoplastic cells, most of which were large,
and round to oval in shape. Some neoplastic giant cells
were observed. The cytoplasm was usually abundant,
and the nuclei were generally large and round with a
prominent nucleolus. The chromatin was hyperchro-
matic, coarse, and granular. Mitotic figures were easily
observed. Remaining lymphoid follicles were found.
IHC phenotypes showed the following results: CD68++,
MAC387++, lysozyme+, vimentin+, CK–, CD4–,
CD5–, CD10–, CD15–, CD21–, CD23–, CD35–,
CD30–, CD38–, CD138–, CD163–, CD56–, ALK–,
CD79a–, CD1a–, TDT–, myeloperoxidase–, LCA–,
CD20–, CD3–, HMB45–, S-100–, and Ki67 25 % (Fig. 2).
The patient was therefore diagnosed with HS. He received
systemic chemotherapy (CHOP regimen), consisting of
vindesine, cyclophosphamide, and epirubicin on day 1 and
prednisone on days 1–5. After 2 courses of chemotherapy,
the enlarged cervical lymph nodes appeared to shrink
and his peripheral blood parameters improved. After
4 courses, FDG-PET reexamination showed partial
remission; BM showed disappearance of abnormal
hematopoiesis, although 2 % blasts remained (Fig. 1b). As
the patient refused to undergo stem cell transplantation,
he underwent 4 additional courses of chemotherapy. His
lymphadenopathy and pancytopenia recurred in March
2013, just a month after his last chemotherapy dose. The
patient refused to undergo another lymph node biopsy.
He was diagnosed with recurrent HS and treated succes-
sively with ICE, GDP, and Dexa-BEAM chemotherapy reg-
imens, during which his peripheral WBC and blasts in
BM gradually increased, although his lymph nodes shrunk.
He was hospitalized again with body aches in December
2013. A complete blood count showed leukocytosis (WBC
count: 50.72 × 109/L; hemoglobin: 9.9 g/d; platelets 49 ×
109/L; 41 % blasts), and BM showed hypercellularity with
50 % blasts, the cytoplasm of which contained many Auer
bodies, whereas the erythroid and megakaryocytic series
were suppressed. These blast cells were positive for perox-
idase and non-specific esterase (Fig. 3); periodic acid-
Fig. 1 Comparison of cytology of bone marrow cells before and after treatment of HS (×1,000, Wright–Giemsa stain). a A bone marrow smear on
first admission showed there were granulocytic predominance and no significant increase in monocytes. There was abnormal hematopoiesis in
granulocyte, erythroid and megakaryocytic series in different extent with 3 % blasts. b A bone marrow smear after 4 courses of CHOP chemotherapy
showed abnormal hematopoiesis was disappeared, although 2 % blasts remained
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Fig. 2 Histologic picture and immunohistochemistry panel of a right cervical lymph node. The node structure was disrupted with effacement by
diffuse distribution of pleomorphic neoplastic cells (×200, H&E) (a), most of which were large, and round to oval in shape. Some neoplastic giant
cells were observed. The cytoplasm was usually abundant, and the nuclei were generally large and round with a prominent nucleolus. The
chromatin was hyperchromatic, coarse, and granular. Mitotic figures were easily observed. Remaining lymphoid follicles were found (×400, H&E)
(b). IHC phenotype of neoplastic cells show positive for CD68 (c), MAC387 (d), lysozyme (e), but negative for myeloperoxidase (f)
Fig. 3 A smear preparation of a bone marrow aspirate in leukemic-phase in December, 2013. a The peripheral blood showed atypical blast cells
with rich plasma, irregular nuclei and conspicuous nucleoli. The percentage of blast cells amounted to 41 % ( ×1,000, Wright–Giemsa stain). b Bone
marrow was packed with pleomorphic large cells with abundant and basophilic cytoplasm containing some Auer bodies (×1,000, Wright–Giemsa stain).
c These cells are positive for peroxidase staining (×1,000). d These cells are positive for non-specific esterase as monocytes (×1,000)
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Schiff staining showed fine grains. FCM analysis showed
abnormal cells positive for CD117, CD13, CD33, HLA-
DR, CD34, CD11c, CD38, and myeloperoxidase, but
negative for CD68. Based on the morphologic and FCM
findings, the patient was diagnosed with AMoL-M5,
and treated with low-dose cytarabine, aclarubicin, and
granulocyte colony-stimulating factor (CAG) regimen
combined with decitabine. He died of severe pneumonia
and hepatic failure in May 2014.
Discussion
HS is an extremely rare malignant neoplasm. Tumors
can occur over a wide range of ages (median age:
46 years), and is more common in males [17]. Clinical
presentation can vary greatly, from isolated lymph node
involvement to rapidly progressive disseminated extra-
nodal disease. The gastrointestinal tract, spleen, soft tis-
sue, and skin are the most common extranodal sites
involved, although other locations have been infre-
quently reported [17]. Some patients also show systemic
symptoms such as fever, fatigue, night sweats, and
weight loss. Cytopenias are reported in about 30 % of
patients with HS [18]. Generally, most patients with dis-
seminated disease die within 2 years, whereas those with
localized disease may benefit from surgery or chemo-
therapy (with or without radiotherapy), and thus have a
relatively indolent clinical course [19].
The WHO classification strictly specifies the origin of
the HS neoplastic cells to exclude diseases originating
from cells other than histiocytes/macrophages, such as
Langerhans cell tumor, follicular dendritic cell sarcoma,
non-Hodgkin lymphoma, malignant melanoma, and
monocytic leukemia. These neoplasms are mainly differ-
entiated by IHC phenotypes, as doing so through morph-
ology alone is difficult. Among them, HS and monocytic
leukemia have some similarities in their IHC phenotypes,
as both can express one or more monocytic neoplasm an-
tigens, such as CD68, CD163 and lysozyme. However,
AMoL, but not HS, commonly also expresses myeloid
markers, such as myeloperoxidase, CD13, CD33, CD117.
Myeloid marker expression is therefore the key to differ-
entiating these two neoplasms.
Although HS is a rare disease, many reports in recent
years have described HS arising subsequent to or con-
current with other neoplasms [3–13], most of which are
lymphocytic leukemia/lymphoma. As HS coexists so
commonly with other neoplasms, many hypotheses have
been proposed regarding the mechanism of HS develop-
ment. The first form is genuine HS, which is the malig-
nant transformation of tissue histiocytes and apparently
includes most cases of isolated HS. The second form is
transdifferentiated HS, which results from transdifferentia-
tion from other lineage neoplasms. This mechanism can
be deduced from studies that showed the coexistence of
HS with follicular lymphoma [3], B-cell acute lympho-
blastic leukemia [8, 9, 11], and chronic lymphocytic
leukemia [12], in which the HS was shown to share mo-
lecular or cytogenetic features with associated neoplasms.
The third form is HS arising from pluripotential germ
cells, which has been proposed because HS can occur
in patients with mediastinal germ cell tumors [14, 15].
Only one case of HS to date was reportedly associated
with monocytic leukemia. Mori et al. [13] described a
70-year-old man with peri-vertebral tumors and periph-
eral monocytosis of >1.0 × 109/L. Pathologic findings
from a needle-biopsied tumor specimen supported the
diagnosis of HS. However, the BM aspirate showed that
both HS and CMML cells carried karyotypic abnormal-
ities involving chromosome 8, indicating the existence
of a common genetic background for both of them; this
study proposed a new form of HS, termed transform-
ation from monocytic neoplasm. Doll et al. [20] also re-
ported a case of chronic myelomonocytic leukemia
terminating as malignant histiocytosis, but IHC testing
was not sufficient to prove the diagnosis of HS.
To our knowledge, AMoL has not been among the tu-
mors reportedly associated with HS. In the present case,
the initial lymph node biopsy showed typical morpho-
logical and immunophenotypic features of HS. Neoplastic
histiocytes were positive for more than one histiocytic
marker, including CD68, MAC387, and lysozyme. The pa-
tient’s specimens were typically devoid of Langerhans
cells, follicular dendritic cells, specific B- and T-cell
markers, and myeloid lineage markers, thus indicating a
definitive diagnosis of HS. Lymphadenopathy and pan-
cytopenia reoccurred 7 months later, and then leukocytes
increased gradually. The BM showed the blasts had typical
Auer bodies, positive for peroxidase and non-specific es-
terase. FCM analysis of BM also showed these cells to be
positive for myeloid markers, thus establishing diagnosis
of AMoL. Although no biopsy data showed whether the
recurred lymphadenopathy was caused by HS relapse or
to AMoL infiltration, the diagnosis of two neoplasms for
the patient was clear from the typical manifestation of the
primitive lymph node pathologic findings and the subse-
quent morphology, IHC phenotypes and FCM findings
from the BM sample.
Monocyte/macrophage series derived from hematopoietic
stem cells, which produce promonocytes that mature
in the BM to monocytes, briefly circulate in the
blood, and then enter tissues as macrophages to
complete the maturation process [21]. If a patient
suffers two homogenous neoplasms, HS and AMoL in
a short period of time,we suspect that a promonocyte
or stem cell, the upstream of both histiocytes and
monocytes,might have malignantly transformed. If so,
the mechanism is different from HS transformed from
monocytic neoplasm proposed by Mori et al. [13],
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because HS occurred not after, but before, or at least
simultaneously with the AMoL.
Unfortunately, we had not acquired cytological and
molecular data from the lymph node and BM to prove
the association of the two neoplasms directly. Moreover,
CD68, one of the common monocyte/macrocyte anti-
gens, was incongruous in the primitive lymph node IHC
phenotypes and the FCM of leukemic-phase BM. The
discrepancy might indicate these two neoplasms unre-
lated, but could also be due to a subtle distinction be-
tween HS and AMoL in CD68 expression (HS: ~100 %;
AMoL: relatively lower) because of different differenti-
ation stages [18]. We regret not being able to perform a
bone marrow biopsy in the leukemic phase, as expres-
sion of histiocyte/macrophage markers, such as Mac 387
and lysozyme, would have shed some light here. Never-
theless, the potential association of both neoplasms in
the present case couldn’t be eliminated.
The rarity of HS makes it difficult to establish standard
treatment. Surgical resection with or without radiation
therapy is the main treatment for localized disease and
CHOP is often used as first-line chemotherapy for HS pa-
tients with advanced disease [19]. However, HS patients
often relapse after CHOP and may require additional
therapies, such as second-line chemotherapy and autolo-
gous hematopoietic stem-cell transplantation [22–24].
Additionally, thalidomide [23, 24], alemtuzumab (an anti-
CD52 monoclonal antibody) [25] and the other novel
targeted therapies including imatinib, sorrafenib and
bevacizaumab [26] had also been reported to be thera-
peutic; however, the prognosis is generally poor. The
patient with a combination of HS and CMML [13], and
the present case, both had transient remission after
chemotherapy. Development of an effective new ther-
apy will be challenging.
Conclusions
To our knowledge, this is the first case of HS combined
with AMoL. The coexistence of these two neoplasms
can be proved by the typical biopsy findings of lymph
node and the myeloid markers of BM. The patient had a
transient response to the chemotherapy and a poor
prognosis. Whether these two homogenous neoplasms
were inherently related is unclear. If so, we suspect this
combination might be caused by malignant transform-
ation of a promonocyte or stem cell, upstream of the
histiocyte and monocyte.
Consent
Written informed consent was obtained from the imme-
diate family members of the patient for publication of
this Case Report and any accompanying images. A copy
of the written consent is available for review by the
Editor-in-Chief of this journal.
Abbreviations
AMoL: Acute monocytic leukemia; HS: Histiocytic sarcoma; BM: Bone marrow;
FCM: Flow cytometry; CD: Cluster of differentiation; FDG-PET: Fluorodeoxyglucose-
positron emission tomography imaging; IHC: Immunohistochemical; WBC: White
blood count; WHO: World Health Organization; CMML: Chronic myelomonocytic
leukemia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JZ, XN and ZW cared for the patient, contributed to concept and design.
JZ and XN drafted the report. HL and XL helped to interpret the patient data
and made relevant corrections. All authors read and approved the final
manuscript.
Author details
1Department of Hematology, Zhongshan Hospital of Xiamen University,
Xiamen 361004, Fujian, China. 2Department of Pathology, Zhongshan
Hospital of Xiamen University, Xiamen 361004, Fujian, China. 3Clinical
Laboratories, Zhongshan Hospital of Xiamen University, Xiamen 361004,
Fujian, China.
Received: 19 May 2015 Accepted: 9 July 2015
References
1. Grogan TM, Pileri SA, Chan JKC, Weiss LM, Fletcher CDM. Histiocytic
sarcoma. In: Swerdlow SH CE, Harris NL, et al., editors. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International
Agency for Research on Cancer; 2008. p. 356–7.
2. Weiss LM, Grogan TM, Mueller-Hermelink H-K. Histiocytic sarcoma. In: Jeff ES,
Harris NL, Stein H, Vardiman JW, et al., editors. World Health Organization
classification of tumors: pathology and genetics of tumors of haematopoietic
and lymphoid tissues. Lyon: International Agency for Research on Cancer Press;
2001. p. 278–9.
3. Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, et al.
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas:
evidence for transdifferentiation of the follicular lymphoma clone. Blood.
2008;111:5433–9.
4. Zhang D, McGuirk J, Ganguly S, Persons DL. Histiocytic/dendritic cell
sarcoma arising from follicular lymphoma involving the bone: a case report
and review of literature. Int J Hematol. 2009;89:529–32.
5. Hure MC, Elco CP, Ward D, Hutchinson L, Meng X, Dorfman DM, et al.
Histiocytic sarcoma arising from clonally related mantle cell lymphoma.
J Clin Oncol. 2012;30:e49–53.
6. Alvaro T, Bosch R, Salvado MT, Piris MA. True histiocytic lymphoma of the
stomach associated with low-grade B-cell mucosa-associated lymphoid
tissue (MALT)-type lymphoma. Am J Surg Pathol. 1996;20:1406–11.
7. Wang E, Papalas J, Hutchinson CB, Kulbacki E, Huang Q, Sebastian S, et al.
Sequential development of histiocytic sarcoma and diffuse large b-cell
lymphoma in a patient with a remote history of follicular lymphoma with
genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic
transformation of an indolent B-cell lymphoma in a single individual. Am J
Surg Pathol. 2011;35:457–63.
8. McClure R, Khoury J, Feldman A, Ketterling R. Clonal relationship between
precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a
case report and discussion in the context of similar cases. Leuk Res.
2010;34:e71–3.
9. Bouabdallah R, Abena P, Chetaille B, Aurran-Schleinitz T, Sainty D, Dubus P,
et al. True histiocytic lymphoma following B-acute lymphoblastic leukaemia:
case report with evidence for a common clonal origin in both neoplasms.
Br J Haematol. 2001;113:1047–50.
10. Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, et al.
Clinicopathologic features of histiocytic lesions following ALL, with a review
of the literature. Pediatr Dev Pathol. 2010;13:225–37.
11. Kumar R, Khan SP, Joshi DD, Shaw GR, Ketterling RP, Feldman AL. Pediatric
histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic
leukemia with homozygous deletion of CDKN2A encoding p16INK4A.
Pediatr Blood Cancer. 2011;56:307–10.
Zhao et al. Diagnostic Pathology  (2015) 10:110 Page 5 of 6
12. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, et al. Clonally
related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/
small lymphocytic lymphoma: a study of seven cases. Mod Pathol.
2011;24:1421–32.
13. Mori M, Matsushita A, Takiuchi Y, Arima H, Nagano S, Shimoji S, et al.
Histiocytic sarcoma and underlying chronic myelomonocytic leukemia: a
proposal for the developmental classification of histiocytic sarcoma.
Int J Hematol. 2010;92:168–73.
14. Song SY, Ko YH, Ahn G. Mediastinal germ cell tumor associated with
histiocytic sarcoma of spleen: case report of an unusual association.
Int J Surg Pathol. 2005;13:299–303.
15. Ladanyi M, Roy I. Mediastinal germ cell tumors and histiocytosis. Hum
Pathol. 1988;9:586–90.
16. Fukunaga M, Kato H. Histiocytic sarcoma associated with idiopathic
myelofibrosis. Arch Pathol Lab Med. 2004;128:1167–70.
17. Takahashi E, Nakamura S. Histiocytic sarcoma : an updated literature review
based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53:1–8.
18. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours
of histiocytes and accessory dendritic cells: an immunohistochemical
approach to classification from the International Lymphoma Study Group
based on 61 cases. Histopathology. 2002;41:1–29.
19. Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma:
clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
Am J Surg Pathol. 2004;28:1133–44.
20. Doll DC, Grogan TM, Greenberg BR. Chronic myelomonocytic leukemia
terminating as malignant histiocytosis. Hematol Pathol. 1987;1:183–9.
21. Cline MJ. The White Cell. Cambridge, MA: Harvard University; 1975.
22. Abu-Sanad A, Warsi A, Michel RP, Nahal A, Popradi G, Storring JM, et al.
Long-term remission after autologous stem-cell transplantation for relapsed
histiocytic sarcoma. Curr Oncol. 2012;19:e289–91.
23. Gergis U, Dax H, Ritchie E, Marcus R, Wissa U, Orazi A. Autologous
hematopoietic stem-cell transplantation in combination with thalidomide as
treatment forhistiocytic sarcoma: a case report and review of the literature.
J Clin Oncol. 2011;29:e251–3.
24. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E. Thalidomide for the
treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Am J Hematol. 2007;82:932–3.
25. Shukla N, Kobos R, Renaud T, Teruya-Feldstein J, Price A, McAllister-Lucas L,
et al. Successful Treatment of Refractory Metastatic Histiocytic Sarcoma With
Alemtuzumab. Cancer. 2012;118:3719–24.
26. Schlick K, Aigelsreiter A, Pichler M, Reitter S, Neumeister P, Hoefler G, et al.
Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series
of 4 cases. Onkologie. 2012;35:447–50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhao et al. Diagnostic Pathology  (2015) 10:110 Page 6 of 6
